<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="COVID-19 1.1. SARS-CoV-2: Structure and Similarity to Other Coronaviruses The" exact="infection" post="caused by novel coronavirus, SARS-CoV-2, COVID-19 has turned into"/>
 <result pre="to COVID-19 patients may enhance the mutation rate [14,15]. The" exact="prevalence" post="and genetic diversity of SARS-CoVs in humans, bats and"/>
 <result pre="out of 182 patients who had completely recovered from the" exact="infection" post="and were discharged from hospital were found to be"/>
 <result pre="China reported that cats and ferrets were susceptible to SARS-CoV-2" exact="infection" post="whereas dogs, pigs, chickens and ducks were not permissive"/>
 <result pre="whereas dogs, pigs, chickens and ducks were not permissive to" exact="infection" post="[36]. The World Organization for Animal Health has reported"/>
 <result pre="[36]. The World Organization for Animal Health has reported SARS-CoV-2" exact="infection" post="in farmed minks, dogs, golden Syrian hamsters, cynomolgus and"/>
 <result pre="RT-PCR based molecular diagnostic tests remain a gold standard for" exact="diagnosis" post="of this virus, new serological tests which detect IgM"/>
 <result pre="world. Up until 28th May 2020, a whopping 5,593,631 corona" exact="infection" post="cases are reported. Among them, 95% of cases are"/>
 <result pre="Turkey, Iran and Peru) to total deaths due to corona" exact="infection" post="is nearly 80%. Only seven of the above countries"/>
 <result pre="of the overall deaths in the world due to corona" exact="infection" post="[39]. The distribution of deaths, recovery and active cases"/>
 <result pre="rate of different gender is not known. The rate of" exact="infection" post="in different countries per 100,000 is similar on the"/>
 <result pre="for the age group greater than 50, the number of" exact="infection" post="and death per 100,000 population is very high. In"/>
 <result pre="vaccine available for SARS-CoV-2 for use in humans. The present" exact="treatment" post="employs two-pronged approachâ€&quot;use of antibiotics to prevent secondary infections"/>
 <result pre="has presented conclusive results with sufficient scientific data as a" exact="treatment" post="against COVID-19 [43,47]. Alternatively, repurposing of available antiviral drugs"/>
 <result pre="the development of a non-human primate model to study SARS-CoV-2" exact="infection" post="for testing potential vaccines and antivirals. In addition to"/>
 <result pre="of a non-human primate model to study SARS-CoV-2 infection for" exact="testing" post="potential vaccines and antivirals. In addition to providing a"/>
 <result pre="and rhesus macaques against SARS infection, respectively [49]. Though the" exact="infection" post="model for SARS-CoV-2 in these non-human primates shows successful"/>
 <result pre="model as it requires lower, close to natural dose for" exact="infection" post="and develops advanced respiratory disease [50]. Variation in level"/>
 <result pre="Trials and Challenges In the absence of any effective antiviral" exact="treatment" post="for SARS-CoV-2, development of an effective vaccine seems imperative"/>
 <result pre="any reliable treatment, identification in infected individuals and their subsequent" exact="isolation" post="is the best bet to contain the pandemic. Current"/>
 <result pre="best bet to contain the pandemic. Current diagnostic approaches for" exact="detection" post="of SARS-CoV-2 infections are based on RT-PCR that detects"/>
 <result pre="utilized much for development of diagnostic kits/methods. Though RT-PCR based" exact="diagnosis" post="of SARS-CoV-2 remains the benchmark for diagnosis of the"/>
 <result pre="Though RT-PCR based diagnosis of SARS-CoV-2 remains the benchmark for" exact="diagnosis" post="of the disease, faster serology based diagnostic tests are"/>
 <result pre="based methods, and also its ease of implementation in mass" exact="testing" post="for SARS-CoV-2. The diagnostic kits approved by the FDA,"/>
 <result pre="test report of discharge patients may be due to false-negative" exact="detection" post="of residual RNA fragments of dead virus fragments or"/>
 <result pre="difference in the incubation period of 2019 novel coronavirus (SARS-CoV-2)" exact="infection" post="between travelers to Hubei and non-travelers: The need of"/>
 <result pre="travelers to Hubei and non-travelers: The need of a longer" exact="quarantine" post="periodInfect. Control. Hosp. Epidemiol.202010.1017/ice.2020.81 30.GuanW.-J.NiZ.-Y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.LiuL.ShanH.LeiC.-L.HuiD.S.C.et al.Clinical Characteristics of Coronavirus"/>
 <result pre="COVID-19 outbreak in ChinaJ. Travel Med.202027taaa03710.1093/jtm/taaa03732181488 33.XieZ.Pay attention to SARS-CoV-2" exact="infection" post="in childrenPediatr. Investig.202041410.1002/ped4.12178 34.YuanB.ChenY.ZhangK.WangC.Recurrence of positive SARS-CoV-2 Viral RNA"/>
 <result pre="positive SARS-CoV-2 Viral RNA in recovered COVID-19 patients during medical" exact="isolation" post="observationNat. Res.202011210.21203/rs.3.rs-22829/v1 35.LeroyE.M.Ar GouilhM.BrugÃ¨re-PicouxJ.The risk of SARS-CoV-2 transmission to"/>
 <result pre="on COVID-19World Organisation for Animal HealthParis, France2020Volume 3616 38.TangY.W.SchmitzJ.E.PersingD.H.StrattonC.W.The Laboratory" exact="diagnosis" post="of COVID-19 infection: Current issues and challengesJ. Clin. Microbiol.20205810.1128/JCM.00512-2032245835"/>
 <result pre="on 28 May 2020) 42.WangS.GuoL.ChenL.LiuW.CaoY.ZhangJ.FengL.A case report of neonatal COVID-19" exact="infection" post="in ChinaClin. Infect. Dis.2020ciaa22510.1093/cid/ciaa22532161941 43.RothanH.A.ByrareddyS.N.The epidemiology and pathogenesis of"/>
 <result pre="coronavirus (SARS-CoV-2): A lesson from animal coronavirusesVet. Microbiol.202024410869310.1016/j.vetmic.2020.10869332402329 56.ChangT.W.Recurrent viral" exact="infection" post="(reinfection)N. Engl. J. Med.197128476577310.1056/NEJM1971040828414064323312 Figure 1 (A) Percentage distribution"/>
</results>
